NCT01428037View on ClinicalTrials.gov

Safety and Efficacy Study of Vaginal Misoprostol for Cervical Ripening and Induction of Labor

PHASE3CompletedINTERVENTIONAL
Enrollment

225

Participants

Timeline

Start Date

March 31, 2012

Primary Completion Date

January 31, 2013

Study Completion Date

January 31, 2013

Conditions
Cervical RipeningInduction of Labor
Interventions
DRUG

Placebo

One tablet vaginal inserted at 4 hrly interval with maximum of three doses

DRUG

Misoprostol vaginal Tablet 25 mcg

One tablet vaginal insert at 4 hrly interval with maximum of three doses

Trial Locations (6)

200030

The International Peace Maternity & Child Care of China Welfare Institute, Shanghai

200127

Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai

210009

Zhongda Hospital ,Southeast University, Nanjing

210029

The First Affliated Hospital with Nanjing Meical Uniersity, Nanjing

400038

Southwest Hospital, Chongqing

610072

Sichuan Provincial People's Hospital, Chengdu

All Listed Sponsors
lead

Regenex Pharmaceutical, China

OTHER

NCT01428037 - Safety and Efficacy Study of Vaginal Misoprostol for Cervical Ripening and Induction of Labor | Biotech Hunter | Biotech Hunter